Genmab | GEN - Selling And Administration Expenses

Stock Price
1,702.50
Daily Change
-38.00 -2.18%
Monthly
-9.01%
Yearly
20.40%
Q1 Forecast
1,614.31

Genmab reported DKK144M in Selling and Administration Expenses for its fiscal quarter ending in June of 2025.





Selling And Administration Expenses Change Date
Agios Pharmaceuticals USD 42.97M 1.7M Dec/2025
Amarin USD 17.94M 17.86M Sep/2025
Amgen USD 1.94B 237M Dec/2025
argenx SE USD 429.62M 93.32M Dec/2025
AstraZeneca USD 4.61B 4.46B Dec/2025
Bayer EUR 4.05B 647M Dec/2025
BioMarin Pharmaceutical USD 322.21M 98.79M Dec/2025
Demant DKK 6.09B 135M Dec/2025
Exelixis USD 123.02M 19.9M Dec/2025
Fresenius Medical Care EUR 785M 79.56M Dec/2025
Galapagos EUR 44.42M 9.87M Dec/2025
Genmab DKK 144M 18M Jun/2025
GlaxoSmithKline GBP 2.68B 518M Dec/2025
GN Store Nord DKK 1.45B 41M Dec/2025
GRIFOLS EUR 275.3M 9.7M Dec/2025
Hikma Pharmaceutical USD 288M 149M Dec/2025
Insmed USD 212.48M 26.11M Dec/2025
Merck EUR 1.6B 136M Dec/2025
Novartis USD 3.31B 134M Sep/2025
Regeneron Pharmaceuticals USD 775M 117.2M Dec/2025
Roche Holding CHF 7.28B 3.99B Dec/2025
Sanofi EUR 2.75B 455M Dec/2025
UCB EUR 1.29B 221M Dec/2024